Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2011

01.04.2011 | Epidemiology

Polymorphisms of tumor necrosis factor-alpha and breast cancer risk: a meta-analysis

verfasst von: Chao Shen, Haiming Sun, Donglin Sun, Lidan Xu, Xuelong Zhang, An Liu, Xueyuan Jia, Jing Bai, Feng Chen, Yang Yu, Yan Jin, Jingcui Yu, Songbin Fu

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

We conducted a meta-analysis to assess the association between tumor necrosis factor-alpha (TNF-alpha) gene TNFA −308 (G>A), TNFA −238 (G>A), TNFA −857 (C>T), TNFA −863 (C>A), TNFA −1031 (T>C), TNFA −1210 (A>T) polymorphisms and breast cancer(BC) susceptibility. We also performed subgroup analyses based on ethnicity (Caucasian, Asian, and African). An extensive search was performed to identify all case–control studies investigating such association. Thirteen eligible studies, including 10,236 BC patients and 13,143 controls, were identified. No significant association was observed in all genotypes in worldwide populations, but stratification by ethnicity indicated that the TNFA −308 A allele was associated with a decreased risk of BC compared with the G allele in Caucasian individuals (OR = 0.927, 95%CI = 0.879–0.978). Similar results were obtained when the A/A +A/G genotype was compared with the G/G genotype. In addition, meta-analysis results indicated that the A/A genotype of TNFA −308 was a risk factor for BC in African (A/A vs. G/G OR = 4.085 95%CI = 1.460–11.425; A/A vs. G/A OR = 4.861 95%CI = 1.746–13.527; A/A vs. G/A + G/G OR = 4.246 95%CI = 1.551–11.625), but not in Caucasian or Asian individuals. In conclusion, the results of this meta-analysis indicate that the TNFA −308 A allele may be an important protective factor for BC in European individuals, but it is not likely to confer susceptibility to BC in worldwide populations. In addition, the AA genotype of TNFA −308 may be a risk factor for BC in African individuals. Besides, other polymorphisms were not associated with BC susceptibility.
Literatur
1.
Zurück zum Zitat Colditz GA, Sellers TA, Trapido E (2006) Epidemiology—identifying the causes and preventability of cancer? Nat Rev Cancer 6(1):75–83PubMedCrossRef Colditz GA, Sellers TA, Trapido E (2006) Epidemiology—identifying the causes and preventability of cancer? Nat Rev Cancer 6(1):75–83PubMedCrossRef
2.
Zurück zum Zitat Welch DR, Steeg PS, Rinker-Schaeffer CW (2000) Molecular biology of breast cancer metastasis. Genetic regulation of human breast carcinoma metastasis. Breast Cancer Res 2(6):408–416PubMedCrossRef Welch DR, Steeg PS, Rinker-Schaeffer CW (2000) Molecular biology of breast cancer metastasis. Genetic regulation of human breast carcinoma metastasis. Breast Cancer Res 2(6):408–416PubMedCrossRef
3.
Zurück zum Zitat Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72(9):3666–3670PubMedCrossRef Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72(9):3666–3670PubMedCrossRef
4.
Zurück zum Zitat Bazzoni F, Beutler B (1996) The tumor necrosis factor ligand and receptor families. N Engl J Med 334(26):1717–1725PubMedCrossRef Bazzoni F, Beutler B (1996) The tumor necrosis factor ligand and receptor families. N Engl J Med 334(26):1717–1725PubMedCrossRef
5.
Zurück zum Zitat Strieter RM, Kunkel SL, Bone RC (1993) Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med 21(10 Suppl):S447–S463PubMedCrossRef Strieter RM, Kunkel SL, Bone RC (1993) Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med 21(10 Suppl):S447–S463PubMedCrossRef
6.
Zurück zum Zitat Ardizzoia A, Lissoni P, Brivio F, Tisi E, Perego MS, Grassi MG, Pittalis S, Crispino S, Barni S, Tancini G (1992) Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease. J Biol Regul Homeost Agents 6(3):103–107PubMed Ardizzoia A, Lissoni P, Brivio F, Tisi E, Perego MS, Grassi MG, Pittalis S, Crispino S, Barni S, Tancini G (1992) Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease. J Biol Regul Homeost Agents 6(3):103–107PubMed
7.
Zurück zum Zitat Raabe T, Bukrinsky M, Currie RA (1998) Relative contribution of transcription and translation to the induction of tumor necrosis factor-alpha by lipopolysaccharide. J Biol Chem 273(2):974–980PubMedCrossRef Raabe T, Bukrinsky M, Currie RA (1998) Relative contribution of transcription and translation to the induction of tumor necrosis factor-alpha by lipopolysaccharide. J Biol Chem 273(2):974–980PubMedCrossRef
8.
Zurück zum Zitat Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, Mahieu P, Malaise M, De Groote D, Louis R et al (1998) Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 113(3):401–406PubMedCrossRef Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, Mahieu P, Malaise M, De Groote D, Louis R et al (1998) Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 113(3):401–406PubMedCrossRef
9.
Zurück zum Zitat Higuchi T, Seki N, Kamizono S, Yamada A, Kimura A, Kato H, Itoh K (1998) Polymorphism of the 5’-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens 51(6):605–612PubMedCrossRef Higuchi T, Seki N, Kamizono S, Yamada A, Kimura A, Kato H, Itoh K (1998) Polymorphism of the 5’-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens 51(6):605–612PubMedCrossRef
10.
Zurück zum Zitat Kohaar I, Tiwari P, Kumar R, Nasare V, Thakur N, Das BC, Bharadwaj M (2009) Association of single nucleotide polymorphisms (SNPs) in TNF-LTA locus with breast cancer risk in Indian population. Breast Cancer Res Treat 114(2):347–355PubMedCrossRef Kohaar I, Tiwari P, Kumar R, Nasare V, Thakur N, Das BC, Bharadwaj M (2009) Association of single nucleotide polymorphisms (SNPs) in TNF-LTA locus with breast cancer risk in Indian population. Breast Cancer Res Treat 114(2):347–355PubMedCrossRef
11.
Zurück zum Zitat Mestiri S, Bouaouina N, Ahmed SB, Khedhaier A, Jrad BB, Remadi S, Chouchane L (2001) Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma. Cancer 91(4):672–678PubMedCrossRef Mestiri S, Bouaouina N, Ahmed SB, Khedhaier A, Jrad BB, Remadi S, Chouchane L (2001) Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma. Cancer 91(4):672–678PubMedCrossRef
12.
Zurück zum Zitat Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719–748PubMed Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719–748PubMed
13.
Zurück zum Zitat DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188PubMedCrossRef DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188PubMedCrossRef
14.
Zurück zum Zitat Munafo MR, Clark TG, Flint J (2004) Assessing publication bias in genetic association studies: evidence from a recent meta-analysis. Psychiatry Res 129(1):39–44PubMedCrossRef Munafo MR, Clark TG, Flint J (2004) Assessing publication bias in genetic association studies: evidence from a recent meta-analysis. Psychiatry Res 129(1):39–44PubMedCrossRef
15.
Zurück zum Zitat Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101PubMedCrossRef Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101PubMedCrossRef
16.
Zurück zum Zitat Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634PubMed Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634PubMed
17.
Zurück zum Zitat MARIE-GENICA Consortium (2009) Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. Breast Cancer Res Treat 120(3):727–736 MARIE-GENICA Consortium (2009) Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. Breast Cancer Res Treat 120(3):727–736
18.
Zurück zum Zitat Azmy IA, Balasubramanian SP, Wilson AG, Stephenson TJ, Cox A, Brown NJ, Reed MW (2004) Role of tumour necrosis factor gene polymorphisms (−308 and −238) in breast cancer susceptibility and severity. Breast Cancer Res 6(4):R395–R400PubMedCrossRef Azmy IA, Balasubramanian SP, Wilson AG, Stephenson TJ, Cox A, Brown NJ, Reed MW (2004) Role of tumour necrosis factor gene polymorphisms (−308 and −238) in breast cancer susceptibility and severity. Breast Cancer Res 6(4):R395–R400PubMedCrossRef
19.
Zurück zum Zitat Chouchane L, Ahmed SB, Baccouche S, Remadi S (1997) Polymorphism in the tumor necrosis factor-alpha promotor region and in the heat shock protein 70 genes associated with malignant tumors. Cancer 80(8):1489–1496PubMedCrossRef Chouchane L, Ahmed SB, Baccouche S, Remadi S (1997) Polymorphism in the tumor necrosis factor-alpha promotor region and in the heat shock protein 70 genes associated with malignant tumors. Cancer 80(8):1489–1496PubMedCrossRef
20.
Zurück zum Zitat Gallicchio L, McSorley MA, Newschaffer CJ, Huang HY, Thuita LW, Hoffman SC, Helzlsouer KJ (2007) Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease. Cancer Detect Prev 31(2):95–101PubMedCrossRef Gallicchio L, McSorley MA, Newschaffer CJ, Huang HY, Thuita LW, Hoffman SC, Helzlsouer KJ (2007) Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease. Cancer Detect Prev 31(2):95–101PubMedCrossRef
21.
Zurück zum Zitat Gaudet MM, Egan KM, Lissowska J, Newcomb PA, Brinton LA, Titus-Ernstoff L, Yeager M, Chanock S, Welch R, Peplonska B et al (2007) Genetic variation in tumor necrosis factor and lymphotoxin-alpha (TNF-LTA) and breast cancer risk. Hum Genet 121(3–4):483–490PubMedCrossRef Gaudet MM, Egan KM, Lissowska J, Newcomb PA, Brinton LA, Titus-Ernstoff L, Yeager M, Chanock S, Welch R, Peplonska B et al (2007) Genetic variation in tumor necrosis factor and lymphotoxin-alpha (TNF-LTA) and breast cancer risk. Hum Genet 121(3–4):483–490PubMedCrossRef
22.
Zurück zum Zitat Giordani L, Bruzzi P, Lasalandra C, Quaranta M, Schittulli F, Della Ragione F, Iolascon A (2003) Association of breast cancer and polymorphisms of interleukin-10 and tumor necrosis factor-alpha genes. Clin Chem 49(10):1664–1667PubMedCrossRef Giordani L, Bruzzi P, Lasalandra C, Quaranta M, Schittulli F, Della Ragione F, Iolascon A (2003) Association of breast cancer and polymorphisms of interleukin-10 and tumor necrosis factor-alpha genes. Clin Chem 49(10):1664–1667PubMedCrossRef
23.
Zurück zum Zitat Kamali-Sarvestani E, Merat A, Talei AR (2005) Polymorphism in the genes of alpha and beta tumor necrosis factors (TNF-alpha and TNF-beta) and gamma interferon (IFN-gamma) among Iranian women with breast cancer. Cancer Lett 223(1):113–119PubMedCrossRef Kamali-Sarvestani E, Merat A, Talei AR (2005) Polymorphism in the genes of alpha and beta tumor necrosis factors (TNF-alpha and TNF-beta) and gamma interferon (IFN-gamma) among Iranian women with breast cancer. Cancer Lett 223(1):113–119PubMedCrossRef
24.
Zurück zum Zitat Ostashkin AS, Malivanova TF, Iurchenko VA, Mazurenko NN (2008) Tumor necrosis factor gene polymorphisms in breast cancer patients. Genetika 44(9):1275–1280PubMed Ostashkin AS, Malivanova TF, Iurchenko VA, Mazurenko NN (2008) Tumor necrosis factor gene polymorphisms in breast cancer patients. Genetika 44(9):1275–1280PubMed
25.
Zurück zum Zitat Park KS, Mok JW, Ko HE, Tokunaga K, Lee MH (2002) Polymorphisms of tumour necrosis factors A and B in breast cancer. Eur J Immunogenet 29(1):7–10PubMedCrossRef Park KS, Mok JW, Ko HE, Tokunaga K, Lee MH (2002) Polymorphisms of tumour necrosis factors A and B in breast cancer. Eur J Immunogenet 29(1):7–10PubMedCrossRef
26.
Zurück zum Zitat Scola L, Vaglica M, Crivello A, Palmeri L, Forte GI, Macaluso MC, Giacalone A, Di Noto L, Bongiovanni A, Raimondi C et al (2006) Cytokine gene polymorphisms and breast cancer susceptibility. Ann N Y Acad Sci 1089:104–109PubMedCrossRef Scola L, Vaglica M, Crivello A, Palmeri L, Forte GI, Macaluso MC, Giacalone A, Di Noto L, Bongiovanni A, Raimondi C et al (2006) Cytokine gene polymorphisms and breast cancer susceptibility. Ann N Y Acad Sci 1089:104–109PubMedCrossRef
27.
Zurück zum Zitat Sirotkovic-Skerlev M, Cacev T, Krizanac S, Kulic A, Pavelic K, Kapitanovic S (2007) TNF alpha promoter polymorphisms analysis in benign and malignant breast lesions. Exp Mol Pathol 83(1):54–58PubMedCrossRef Sirotkovic-Skerlev M, Cacev T, Krizanac S, Kulic A, Pavelic K, Kapitanovic S (2007) TNF alpha promoter polymorphisms analysis in benign and malignant breast lesions. Exp Mol Pathol 83(1):54–58PubMedCrossRef
28.
Zurück zum Zitat Kopreski MS, Lipton A, Harvey HA, Kumar R (1996) Growth inhibition of breast cancer cell lines by combinations of anti-P185HER2 monoclonal antibody and cytokines. Anticancer Res 16(1):433–436PubMed Kopreski MS, Lipton A, Harvey HA, Kumar R (1996) Growth inhibition of breast cancer cell lines by combinations of anti-P185HER2 monoclonal antibody and cytokines. Anticancer Res 16(1):433–436PubMed
29.
Zurück zum Zitat Pagliacci MC, Fumi G, Migliorati G, Grignani F, Riccardi C, Nicoletti I (1993) Cytostatic and cytotoxic effects of tumor necrosis factor alpha on MCF-7 human breast tumor cells are differently inhibited by glucocorticoid hormones. Lymphokine Cytokine Res 12(6):439–447PubMed Pagliacci MC, Fumi G, Migliorati G, Grignani F, Riccardi C, Nicoletti I (1993) Cytostatic and cytotoxic effects of tumor necrosis factor alpha on MCF-7 human breast tumor cells are differently inhibited by glucocorticoid hormones. Lymphokine Cytokine Res 12(6):439–447PubMed
30.
Zurück zum Zitat Cai Z, Stancou R, Korner M, Chouaib S (1996) Impairment of Fas-antigen expression in adriamycin-resistant but not TNF-resistant MCF7 tumor cells. Int J Cancer 68(4):535–546PubMedCrossRef Cai Z, Stancou R, Korner M, Chouaib S (1996) Impairment of Fas-antigen expression in adriamycin-resistant but not TNF-resistant MCF7 tumor cells. Int J Cancer 68(4):535–546PubMedCrossRef
31.
Zurück zum Zitat Hagihara M, Shimura T, Sato K, Genga K, Suzuki M, Tsuji K (1995) HLA and tumor necrosis factor beta gene polymorphisms in Okinawa lung cancer patients: comparative study with mainland Japan lung cancer patients. Hum Immunol 43(2):95–100PubMedCrossRef Hagihara M, Shimura T, Sato K, Genga K, Suzuki M, Tsuji K (1995) HLA and tumor necrosis factor beta gene polymorphisms in Okinawa lung cancer patients: comparative study with mainland Japan lung cancer patients. Hum Immunol 43(2):95–100PubMedCrossRef
32.
Zurück zum Zitat Messer G, Spengler U, Jung MC, Honold G, Blomer K, Pape GR, Riethmuller G, Weiss EH (1991) Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 173(1):209–219PubMedCrossRef Messer G, Spengler U, Jung MC, Honold G, Blomer K, Pape GR, Riethmuller G, Weiss EH (1991) Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 173(1):209–219PubMedCrossRef
33.
Zurück zum Zitat Ozaki K, Ohnishi Y, Iida A, Sekine A, Yamada R, Tsunoda T, Sato H, Hori M, Nakamura Y, Tanaka T (2002) Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 32(4):650–654PubMedCrossRef Ozaki K, Ohnishi Y, Iida A, Sekine A, Yamada R, Tsunoda T, Sato H, Hori M, Nakamura Y, Tanaka T (2002) Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 32(4):650–654PubMedCrossRef
34.
Zurück zum Zitat Soga Y, Nishimura F, Ohyama H, Maeda H, Takashiba S, Murayama Y (2003) Tumor necrosis factor-alpha gene (TNF-alpha) −1031/−863, −857 single-nucleotide polymorphisms (SNPs) are associated with severe adult periodontitis in Japanese. J Clin Periodontol 30(6):524–531PubMedCrossRef Soga Y, Nishimura F, Ohyama H, Maeda H, Takashiba S, Murayama Y (2003) Tumor necrosis factor-alpha gene (TNF-alpha) −1031/−863, −857 single-nucleotide polymorphisms (SNPs) are associated with severe adult periodontitis in Japanese. J Clin Periodontol 30(6):524–531PubMedCrossRef
35.
Zurück zum Zitat Kaijzel EL, Bayley JP, van Krugten MV, Smith L, van de Linde P, Bakker AM, Breedveld FC, Huizinga TW, Verweij CL (2001) Allele-specific quantification of tumor necrosis factor alpha (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals. Genes Immun 2(3):135–144PubMedCrossRef Kaijzel EL, Bayley JP, van Krugten MV, Smith L, van de Linde P, Bakker AM, Breedveld FC, Huizinga TW, Verweij CL (2001) Allele-specific quantification of tumor necrosis factor alpha (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals. Genes Immun 2(3):135–144PubMedCrossRef
36.
Zurück zum Zitat Uglialoro AM, Turbay D, Pesavento PA, Delgado JC, McKenzie FE, Gribben JG, Hartl D, Yunis EJ, Goldfeld AE (1998) Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-alpha gene promoter. Tissue Antigens 52(4):359–367PubMedCrossRef Uglialoro AM, Turbay D, Pesavento PA, Delgado JC, McKenzie FE, Gribben JG, Hartl D, Yunis EJ, Goldfeld AE (1998) Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-alpha gene promoter. Tissue Antigens 52(4):359–367PubMedCrossRef
Metadaten
Titel
Polymorphisms of tumor necrosis factor-alpha and breast cancer risk: a meta-analysis
verfasst von
Chao Shen
Haiming Sun
Donglin Sun
Lidan Xu
Xuelong Zhang
An Liu
Xueyuan Jia
Jing Bai
Feng Chen
Yang Yu
Yan Jin
Jingcui Yu
Songbin Fu
Publikationsdatum
01.04.2011
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-1184-5

Weitere Artikel der Ausgabe 3/2011

Breast Cancer Research and Treatment 3/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.